Potential genetic markers for prediction of treatment response in Egyptian children infected with HCV genotype 4.
BACKGROUND
Egypt has a high prevalence of hepatitis C virus (HCV) infection. Limitations of the current HCV treatment in children are low rate of sustained virological response, significant side effects and high expenses, making prediction of treatment response crucial.


OBJECTIVE
This study aimed to investigate association of single nucleotide polymorphisms (SNPs) in interleukins (IL) 10, 28 and 29 genes in predicting the response to therapy in HCV infected children.


METHODS
Sixty-six Egyptian children infected with HCV genotype 4, receiving pegylated interferon alpha 2b and ribavirin, were included. Genotyping of six SNPs in interleukin 10, 28B and 29 gene as well as HCV genotype were analyzed by real-time polymerase chain reaction.


RESULTS
The CC genotype in IL28B; rs12979860 had 8.547 folds higher chance to develop sustained virological response than CT and TT genotypes (P=0.014). Genotype distribution of rs8099917 in IL28B gene (TG and GG genotypes) was found to be 3.348 more likely not to respond to treatment than the TT genotype (P=0.018). In multivariate analysis, interleukin 28 gene single nucleotide polymorphisms rs 12979860, interleukin 10 single nucleotide polymorphisms -592A > C and basal viral load were independent variables that significantly improved prediction of response to HCV therapy.


CONCLUSIONS
This association can be translated into clinical decision making for HCV treatment.
Department of Clinical and Chemical Pathology, Kasr Alainy Medical School, Cairo University, Cairo, Egypt.
Normeen Hany
NH
Rady
Department of Clinical and Chemical Pathology, Kasr Alainy Medical School, Cairo University, Cairo, Egypt.
Rania Kamal
RK
Darwish
Department of Pediatrics, Kasr Alainy Medical School, Cairo University, Cairo, Egypt.
Engy Adel
EA
Mogahed
Department of Clinical and Chemical Pathology, Kasr Alainy Medical School, Cairo University, Cairo, Egypt.
Iman Atef
IA
Mandour
Department of Clinical and Chemical Pathology, Kasr Alainy Medical School, Cairo University, Cairo, Egypt.
Hazem
H
Abo Youssef
Department of Clinical and Chemical Pathology, Kasr Alainy Medical School, Cairo University, Cairo, Egypt.
Sahar Abdel Atty
SA
Sharaf
Department of Pediatrics, Kasr Alainy Medical School, Cairo University, Cairo, Egypt. Electronic address: hanaakaraksy@kasralainy.edu.eg.
Hanaa Mostafa
HM
El-Karaksy
D000293:Adolescent; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004534:Egypt / Q000453:epidemiology; D005260:Female; D005787:Gene Frequency; D005819:Genetic Markers / Q000235:genetics; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons; D016753:Interleukin-10 / Q000235:genetics*; D007378:Interleukins / Q000235:genetics*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D019562:Viral Load / Q000235:genetics; D000095022:Interferon Lambda
D000998:Antiviral Agents; D005819:Genetic Markers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons; D016753:Interleukin-10; D007378:Interleukins; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C508609:IL10 protein, human; C417083:peginterferon alfa-2b
Children; HCV; Interleukin 10; Interleukin 28; SNPs